ipamorelin selective ghrp minimal off-target effects vs GHRP-2 vs GHRP-6: Growth Hormone Secretagog The reason CJC-1295 and ipamorelin

A study published in Clinical Interventions in Aging confirmed that using a GHRH analog (like CJC1295) with a GHRP (like Ipamorelin) can significantly elevate IGF-1 levels over time (Khorram, CIA )

1 2) Human pharmacology: prolonged IGF1 elevation and long half-life (DAC form) In healthy adult volunteers, a placebocontrolled, ascendingdose clinical study reported that a single subcutaneous injection of CJC1295 produced dosedependent, sustained increases in: Research interpretation: this makes CJC1295 (DAC) useful for modeling longerduration receptor stimulation and downstream IGF1 axis activation in controlled research designs

- This research blend combines 8MG Tesamorelin and 2MG Ipamorelin in a GH-axis focused format studied in models involving GHRH pathway activity, growth hormone secretagogue signaling, pituitary-axis research, IGF-1 pathway biology, metabolic regulation, and endocrine signaling

Absence of Human Safety Data No published, peer-reviewed human safety or tolerability data exist for ipamorelin at the time of writing

Treatments such as laser or microneedling create a controlled injury

What research areas use CJC-1295 / Ipamorelin (No DAC)